Rhenium Re 186 etidronate

Drug Profile

Rhenium Re 186 etidronate

Alternative Names: Re 186 HEDP

Latest Information Update: 06 Oct 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mallinckrodt Medical
  • Developer Mallinckrodt Medical; Memorial Sloan-Kettering Cancer Center; University of Cincinnati
  • Class Heavy metals; Non-opioid analgesics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer metastases; Cancer pain

Most Recent Events

  • 06 Oct 2004 Discontinued - Clinical-Phase-Unknown for Cancer metastases in United Kingdom (Injection)
  • 06 Oct 2004 Discontinued - Preregistration for Cancer pain in USA (Injection)
  • 01 Feb 2002 A study has been added to the Pain Control therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top